Literature DB >> 27122954

The Association between Serum Ferritin Level, Tissue Doppler Echocardiography, Cardiac T2* MRI, and Heart Rate Recovery in Patients with Beta Thalassemia Major.

Isa Oner Yuksel1, Erkan Koklu1, Erdal Kurtoglu2, Sakir Arslan1, Goksel Cagirci1, Volkan Karakus2, Gorkem Kus1, Serkan Cay3, Selcuk Kucukseymen1.   

Abstract

BACKGROUND: It is generally well-understood that iron-mediated cardiomyopathy is the major complication that can arise from beta thalassemia major (TM). Therefore, early diagnosis, risk stratification, and the effective treatment of beta TM patients are clinically important to optimize long-term positive outcomes.
METHODS: This study included 57 beta TM patients with a mean age of 25 ± 7 years. We determined the serum ferritin level, echocardiography, heart rate recovery (HRR), and cardiac magnetic resonance (CMR) T2* in all patients. CMR T2* findings were categorized as normal myocardium (T2* > 20 ms), and myocardial involvement (T2* ≤ 20 ms). HRR values at 1-5 min (HRR1-5) were recorded; Subsequently. HRR was calculated by subtracting the heart rate at each time point from the heart rate at peak exercise.
RESULTS: There was a significant negative correlation between the serum ferritin level and the cardiac T2* MRI findings (r = -0.34, p = 0.009). A similar result was found in the negative correlation between serum ferritin and all heart rate recovery values. There was a significant positive correlation between HRR1, HRR2, and HRR3 values, and CMR T2* (T2* heart rate recovery (HRR)1: r = 0.51, p < 0.001; T2* HRR2: r = 0.48, p < 0.001; T2* HRR3: r = 0.47, p < 0.001, respectively).
CONCLUSIONS: The serum ferritin level and echocardiography can be used to predict the presence of myocardial iron load in beta TM patients. Therefore, HRR can be used to screen beta TM patients, and the clinical use of HRR can be a predictive marker for autonomic dysfunction in beta TM patients. KEY WORDS: Beta thalassemia major • Cardiac magnetic resonance T2* • Heart rate recovery • Iron overload • Serum ferritin level • Tissue Doppler imaging.

Entities:  

Year:  2016        PMID: 27122954      PMCID: PMC4816922          DOI: 10.6515/acs20150824a

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  33 in total

1.  Relationship between color M-mode echocardiography flow propagation and cardiac iron load on MRI in patients with thalassemia major.

Authors:  Orhan Ozbek; Kadir Acar; Mehmet Kayrak; Seda Ozbek; Enes Elvin Gül; Ramazan Uçar; Yahya Paksoy
Journal:  Diagn Interv Radiol       Date:  2011-10-17       Impact factor: 2.630

2.  Myocardial iron loading in patients with thalassemia major on deferoxamine chelation.

Authors:  M A Tanner; R Galanello; C Dessi; M A Westwood; G C Smith; S V Nair; L J Anderson; J M Walker; D J Pennell
Journal:  J Cardiovasc Magn Reson       Date:  2006       Impact factor: 5.364

Review 3.  The population genetics of the haemoglobinopathies.

Authors:  J Flint; R M Harding; A J Boyce; J B Clegg
Journal:  Baillieres Clin Haematol       Date:  1998-03

Review 4.  Iron-chelating therapy for transfusional iron overload.

Authors:  Gary M Brittenham
Journal:  N Engl J Med       Date:  2011-01-13       Impact factor: 91.245

5.  Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia.

Authors:  B A Davis; J B Porter
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

6.  Iron-chelation therapy with oral deferiprone in patients with thalassemia major.

Authors:  N F Olivieri; G M Brittenham; D Matsui; M Berkovitch; L M Blendis; R G Cameron; R A McClelland; P P Liu; D M Templeton; G Koren
Journal:  N Engl J Med       Date:  1995-04-06       Impact factor: 91.245

7.  Cardiac involvement in secondary haemochromatosis: a catheter biopsy study and analysis of myocardium.

Authors:  D H Fitchett; D J Coltart; W A Littler; M J Leyland; T Trueman; D I Gozzard; T J Peters
Journal:  Cardiovasc Res       Date:  1980-12       Impact factor: 10.787

8.  Longitudinal analysis of heart and liver iron in thalassemia major.

Authors:  Leila J Noetzli; Susan M Carson; Anne S Nord; Thomas D Coates; John C Wood
Journal:  Blood       Date:  2008-07-23       Impact factor: 22.113

9.  Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major.

Authors:  P Kirk; M Roughton; J B Porter; J M Walker; M A Tanner; J Patel; D Wu; J Taylor; M A Westwood; L J Anderson; D J Pennell
Journal:  Circulation       Date:  2009-10-02       Impact factor: 29.690

10.  Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.

Authors:  Mark A Tanner; Renzo Galanello; Carlo Dessi; Gillian C Smith; Mark A Westwood; Annalisa Agus; Martina Pibiri; Sunil V Nair; J Malcolm Walker; Dudley J Pennell
Journal:  J Cardiovasc Magn Reson       Date:  2008-02-25       Impact factor: 5.364

View more
  9 in total

1.  Heart Rate Recovery as a Novel Test for Predicting Cardiac Involvement in Beta-Thalassemia Major.

Authors:  Selcuk Kucukseymen; Isa Oner Yuksel; Goksel Cagirci; Erkan Koklu; Volkan Karakus; Serkan Cay; Gorkem Kus; Erdal Kurtoglu; Sakir Arslan
Journal:  Acta Cardiol Sin       Date:  2017-07       Impact factor: 2.672

2.  Impact of Genotype of Beta Globin Gene on Hepatic and Myocardial Iron Content in Egyptian Patients with Beta Thalassemia.

Authors:  Tamer H Hassan; Mohamed M Abdel Salam; Marwa Zakaria; Mohamed Shehab; Dina T Sarhan; El Sayed H Zidan; Khaled M El Gerby
Journal:  Indian J Hematol Blood Transfus       Date:  2018-11-08       Impact factor: 0.900

3.  Evaluation of electrocardiography, echocardiography and cardiac T2* for cardiac complications in beta thalassemia major.

Authors:  Fadime Ersoy Dursun; Gönül Açıksarı; Serçin Özkök; Onur İncealtın
Journal:  Int J Cardiovasc Imaging       Date:  2021-10-08       Impact factor: 2.357

4.  Evaluation of Erectile Dysfunction and Left Ventricular Diastolic Parameters in Lead Exposed Workers.

Authors:  Ugur Nadir Karakulak; Sercan Okutucu; Utku Lokman; Ovunc Bilgin; Engin Tutkun; Omer Hinc Yilmaz; Ali Oto
Journal:  Acta Cardiol Sin       Date:  2019-01       Impact factor: 2.672

5.  Evaluation of iron overload by cardiac and liver T2* in β-thalassemia: Correlation with serum ferritin, heart function and liver enzymes.

Authors:  Hengameh Khadivi Heris; Babak Nejati; Khatereh Rezazadeh; Hossein Sate; Roya Dolatkhah; Zohreh Ghoreishi; Ali Esfahani
Journal:  J Cardiovasc Thorac Res       Date:  2021-02-18

6.  Cardiopulmonary testing in adult patients with β-thalassemia major in comparison to healthy subjects.

Authors:  G Piatti; M Giuditta; D Consonni; E Cassinerio; M D Cappellini
Journal:  Ann Hematol       Date:  2022-09-13       Impact factor: 4.030

7.  Cardiovascular magnetic resonance native T2 and T2* quantitative values for cardiomyopathies and heart transplantations: a systematic review and meta-analysis.

Authors:  G J H Snel; M van den Boomen; L M Hernandez; C T Nguyen; D E Sosnovik; B K Velthuis; R H J A Slart; R J H Borra; N H J Prakken
Journal:  J Cardiovasc Magn Reson       Date:  2020-05-11       Impact factor: 5.364

8.  Effective method of evaluating myocardial iron concentration in pediatric patients with thalassemia major.

Authors:  Arwa Khaled; Dina A Ezzat; Hoda A Salem; Hadeel M Seif; Hoda Rabee
Journal:  J Blood Med       Date:  2019-07-12

9.  Cardiac MRI T2* in Liver Transplant Candidates: Application and Performance of a Novel Imaging Technique to Identify Patients at Risk for Poor Posttransplant Cardiac Outcomes.

Authors:  Sara M Lewin; Kimberly Kallianos; M Ilan Nevah; Susan Zhao; Oren K Fix; Gabriel C Brooks; Teresa De Marco; Atif N Qasim; Karen G Ordovas; Neil Mehta
Journal:  Transplant Direct       Date:  2018-06-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.